Conn’s adenoma in a woman with celiac disease

Taoufiq Aatif**, Salah Bellasri¹, Youness El Harrech³

Abstract
Conn’s adenoma on a field of celiac disease has never been described in the literature. We report a case of 31-year-old woman with a history of celiac disease under gluten-free diet, and a pregnancy-induced hypertension controlled under treatment. She was presented with hypertension crisis, hypokalemia and metabolic alkalosis. Diagnosis of primary aldosteronism (PA) was suspected, which was confirmed by a decrease plasma renin, elevated plasma aldosterone level and high aldosterone/renin ratio additionally. Adrenal computed tomography revealed left adrenal mass. The patient was treated with nicardipine, spironolactone and potassium supplements. Laparoscopic left adrenalectomy was performed. The final diagnosis was adenoma of the adrenal gland consistent with Conn’s adenoma. Blood pressure (BP) and hypokalemia returned to the normal level without any medication or supplement.

Keywords: Conn’s adenoma, Primary aldosteronism, Hypertension, Hypokalemia, Metabolic alkalosis

Citation: Aatif T, Bellasri S, Harrech Y. Conn’s adenoma in a woman with celiac disease. J Renal Endocrinol. 2019;5:e02.

Copyright © 2019 The Author(s); Published by Nickan Research Institute. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction
The aldosterone-producing adenoma (APA), the second most important cause of primary aldosteronism (PA), was first reported by Conn in 1955 (1,2). Currently, it is one of the few potentially curable causes of secondary arterial hypertension. It is a clinical syndrome characterized by hypertension, hypokalemia, by excessive urinary excretion of potassium, and metabolic alkalosis. We report a case of a woman with a history of celiac disease with evolving pregnancy-induced hypertension one year before admission. She then developed secondary hypertension with hypertension crisis, secondary to an APA.

Case Presentation
She was a 31-year-old female, with a history of celiac disease under gluten-free diet, and a pregnancy-induced hypertension one year ago, without having been screened for secondary hypertension, to the best of our knowledge. A satisfactory blood pressure (BP) has been reached under treatment with nicardipine (100 mg/d). Shewas admitted to our hospital because of headache, muscle weakness and heart palpitations, for 2 weeks. On physical examination, She was in regular general condition and with a healthy coloring. Her weight was 53.5 kg and height 162 cm (body mass index [BMI]=20.41 kg/m²). BP measured was 190/110 mm Hg, heart rate; 100 beats/minute and regular, respiratory rate; 18 cycles/min and body temperature was 36.9°C. On auscultation, her lungs were clear with no rales. Her heart auscultation showed regular cardiac rhythm with cardiac sounds of normal intensity and no murmurs. Her lower limbs showed symmetric palpable pulses and no edema. The power and sensation of both lower and upper limbs were normal. The abdominal examination showed normal palpation, no visceromegaly and no abdominal murmur. Thyroid gland examination was normal. There was neither obesity nor hirsutism. Other examinations were normal.

Laboratory findings were as follows; serum potassium; 1.68 mEq/L (normal range; 3.5-5.1), sodium; 143 mEq/L (normal range; 136-145), serum bicarbonate; 32 mEq/L(normal range; 22-31), corrected calcium; 95 mg/L(normal range; 86-100), phosphorus; 29.9 mg/L (normal range; 25-45), urea; 0.15 g/L (normal range; 0.13-0.45), creatinine 3.9 mg/L(normal range; 5-9). The complete blood count and coagulation indices were normal. The thyroid function test was normal (0.94 mU/L; normal range; 0.27-4.2). The measurements of sodium and potassium in the 24-hour urine were 54 mEq/L (normal range; 54-190) and 63 mEq/L (normal range; 25-125), respectively. The ECG showed presence of changes of hypokalemia, U waves and no hypertension changes. Echocardiographic assessment for hypertensive heart disease was not detected. There was no hypertensive retinopathy too.

Received: 10 May 2018, Accepted: 19 July 2018, ePublished: 5 July 2018

¹Department of Nephrology and Hemodialysis, 5th Military Hospital Guelmim and Sidi Mohamed Ben Abdellah University, Faculty of Medicine and Pharmacy, Fes, Morocco. ²Department of Radiology 5th Military Hospital Guelmim, Morocco. ³Department of Urology, 5th Military Hospital Guelmim, Morocco

*Corresponding Author: Taoufiq Aatif, Email: taoufiq.aatif@usmba.ac.ma
She was treated with boluses of intravenous potassium chloride and oral potassium supplements for 260 mmol/d over 6 days. Initially her hypertension was treated with intravenous nicardipine using an electrical syringe pump. Despite intravenous and oral potassium supplementation, her serum potassium level remained low. The PA was suspected because of persistence hypokalemia in association with hypertension and alkalosis. However, after correction of serum potassium level, the patient was examined for the plasma aldosterone concentration (PAC) and direct renin concentration (DRC). Results revealed a low DRC level of 0.9 mU/L (normal range; 2.8-39.9), along with a very high PAC level of 2613 pmol/L (normal range: 83-405). The aldosterone to renin ratio (ARR) was 523 pmol/L per mU/L (normal<64). Subsequently, after a three-day oral sodium load, 24-hour urine was tested for the concentration of sodium (260 mmol) and aldosterone (27.3 µg). Abdominal computerized tomography (CT) revealed a 28×21 mm hypodense mass (1UH of density), not enhanced by the contrast product, over the left adrenal gland (Figures 1 and 2). After administration of spironolactone 100 mg/d and nicardipine 150 mg/d for one month preoperatively, the BP became normalized (125/85 mm Hg), the headache, weakness and heart palpitations significantly improved, and the serum level of potassium was 4.5 mEq/L. Therefore, the patient underwent a successful laparoscopic left adrenalectomy (Figure 3). The postoperative course was well. The macroscopic tumor consisted of an ovoid piece of yellow color tissue with weight (28 g), circumscribed mass; 20 × 30 mm in dimensions adjacent to adrenal tissue. Histologically, the adrenal mass showed an encapsulated epithelial neoplasia with cells of clear cytoplasm, round nuclei and conspicuous nucleoli. However, necrosis, capsular invasion while atypical mitosis were not found (Figure 4). The histopathological diagnosis was adenoma of the adrenal gland consistent with Conn’s adenoma. The patient was normotensive and serum potassium was 4.5 mEq/L without any antihypertensive medication or supplement for the last three months after discharge. She was stable with an optimal control of BP without hypokalemia with a 2-year follow-up.

**Discussion**

PA is the cause of approximately 0.05%-2% of all secondary arterial hypertension is characterized by suppressed plasma renin activity and hypokalemia (3). Conn estimated the prevalence of the disorder around 10% of the general population (4). PA includes unilateral adenoma (30%), unilateral (2%) and bilateral (60%) adrenal hyperplasia, familial aldosteronism (1%) and adrenal carcinoma with aldosterone hypersecretion (<1%). The uncontrollable synthesis of aldosterone leads to increased sodium reabsorption, kaliuresis and renin suppression. All of the above challenge arterial hypertension, which affects target organs (heart, kidneys, brain) more gravely than essential hypertension does (5). The APA is a small nodule (<2 cm) that mostly occurs in the left adrenal gland commonly found in females, and usually present with severe hypertension and more profound hypokalemia. It is also more common in younger patients (30-50 years of age).
age), with higher plasma and urinary levels of aldosterone (6,7). Some patients are completely asymptomatic or have minimum symptoms resulting from hypertension (headache) and hypokalemia (polyuria, nocturia, muscle cramps). Occasionally, excessive muscle weakness, paresthesia, tetany, and even muscle paralysis may occur (2,7,8). Usually, PA is characterized by hypertension, hypokalemia, excessive urinary excretion of potassium, hypernatremia, and metabolic alkalosis (7). It is recommended testing for the PA in the following groups; patients with hypertension and hypokalemia, treatment-resistant hypertension (three antihypertensive drugs and poor control), severe hypertension (>160 mm Hg systolic or >100 mm Hg diastolic), hypertension and an incidental adrenal mass, and onset of hypertension at a young age (6).

We described a case of young (31-year-old) female with a pregnancy-induced hypertension one year ago, without having screened for secondary hypertension, and with satisfactory control of BP under treatment with nicardipine, which favors the initial diagnosis of controlled primary hypertension, despite its beginning at an age suggesting secondary hypertension. The occurrence of hypertension crisis with headaches, muscle weakness, heart palpitations, and significant hypokalemia led us to consider a cause of hypertension secondary in origin superimposed on primary hypertension. Despite intravenous and oral potassium supplementation, her serum potassium level remained low. The PA was suspected because of persistence hypokalemia in association with severe hypertension and alkalosis.

Hypokalemia (serum potassium ≤3.5 mmol/L) is only present in a minority of patients with PA (9). However, the frequency of hypokalemia is related to whether PA can be surgically cured. A study with a large series of patients reported that hypokalemia was present in 7%, 17% and 48% of patients with essential hypertension, idiopathic PA, and APA, respectively (10).

Our patient had an association of PA secondary to APA, and celiac disease under gluten-free diet. This association has never been described in the literature. Both diseases can manifest as hypokalemia, PA by excessive urinary excretion of potassium, and celiac disease by malabsorption, which could trigger or aggravate hypokalemia.

The diagnostic approach of PA can be consisted of three steps; the ARR calculation, confirmatory tests of PA and distinction of the disease subtypes. Recent guidelines suggest screening for PA patients with difficult-to-treat or hypokalemic hypertension using the ARR (9). The ARR was introduced by Hiramatsu and colleagues in 1981 as a screening tool to facilitate the diagnosis of PA among hypertensive patients (11). However, using the ARR decreases the intra- and inter-patient variability in renin and aldosterone levels linked to sodium intake, body position and age (12,13). The most frequently used cut-off values for PAC to plasma renin activity (PRA) ratios are in the range of 20 to 50 ng/dl (554 to 1.385 pmol/L) per ng/ml/h; for PAC to direct renin assay (DRA), these values are in the range of 2.4 to 4.9 ng/dl (66 to 136 pmol/L) per mU/L (14). Our patient had a two ARR greater than 136 pmol/L per mU/L. The recent clinical practice guidelines for case detection, diagnosis, and treatment of patients with PA recommend that patients with positive ARR undergo any of four suppression tests to confirm or exclude the diagnosis of PA (14). This implies that PA is defined as a non-suppressible aldosterone excess. The four suppression tests respectively use oral sodium loading, oral fludrocortisone, oral captopril, or saline infusion to suppress aldosterone secretion (9). Oral sodium load test includes the determination of sodium and aldosterone concentration in 24-hour urine, after 3 days of increased salt intake. Values of aldosterone >12 µg and sodium >200 mmol are diagnostic of PA (6). This test confirmed the presence of PA in our patient (aldosterone; 27.3 µg/24 h, sodium 260 mmol/24 h). We did not proceed to saline infusion test (intravenous infusion of 2 L of saline in four hours leads to a PAC rate over 277 pmol/L if PA is present), oral captopril test and fludrocortisone test. The fludrocortisone suppression test is rarely performed in most centers nowadays (6). Distinction of disease subtypes is based on CT, adrenal vein catheterization with venous sampling and genetic screening for the familial types of the disease (14). In our patient, abdominal CT demonstrated a 28×21 mm hypodense mass (1 hounsfield unit [HU] of density), not enhanced by the contrast product, over the left adrenal gland. Unenhanced attenuation values on CT<10 HU indicated adenoma, as carcinoma present with values over 10 HU (15). The presence of an adenoma in patients with PA suggests the presence of an APA, but it cannot exclude the combination of a non-secreting adenoma and idiopathic PA (14-16). For distinction of the disease subtypes, a more practical approach used for the adrenal vein sampling (AVS) as recommended by Young et al (6) which is based on patient preferences, age, adrenal morphologic appearance on CT, clinical comorbid conditions, and clinical probability for finding an APA. For patients younger than 40 years, in whom a solitary adenoma is >1 cm with normal contralateral adrenal gland, a unilateral adrenalectomy may be done without adrenal vein sampling and in the absence of comorbid conditions. Therefore, the adrenal vein sampling was...
bypass in our case based on these criteria. Concerning therapeutic approach, the goal is to prevent the morbidity and mortality associated with hypertension, hypokalemia and cardiovascular damage (17). The cause of the PA helps to determine the appropriate treatment. Normalization of BP should not be the only goal in managing a patient who has PA. In addition to the kidney and the colon, mineralocorticoid receptors occur in the heart, brain and blood vessels. Excessive secretion of aldosterone is associated with increased risk of cardiovascular disease and morbidity. Therefore, normalization of circulating aldosterone or mineralocorticoid receptor blockade should be part of the management plan for all patients with PA (17). Unilateral laparoscopic adrenalectomy is the preferred treatment for patients with APA, and bilateral hyperplasia should be treated with mineralocorticoid antagonists; spironolactone or eplerenone. Cardiovascular morbidity caused by aldosterone excess can be decreased by either unilateral adrenalectomy or mineralocorticoid antagonist. Our patient was treated with laparoscopic left adrenalectomy after using spironolactone 100 mg/d and nicardipine 150 mg/d for one month preoperatively, leading to correction of hypokalemia and optimal control of BP.

Conclusion
PA is the commonest cause of secondary arterial hypertension. APA is the second most important cause of PA and represents one of the few curable causes of secondary hypertension. Patients with PA have higher cardiovascular morbidity and mortality. The identification of the underlying disease of PA is substantial, since unilateral disorders are treated with adrenalectomy, while bilateral disorders are treated conservatively by aldosterone receptor antagonists.

Authors’ contribution
TA and EY managed the patient and prepared the manuscript. SB finalized the paper. All authors read and signed the final manuscript.

Conflicts of interest
There were no points of conflicts.

Ethical considerations
Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the authors. The patient has given her informed consent regarding the publication of this case report.

Funding/Support
None.

References
1. Conn JW. Primary aldosteronism: a new clinical syndrome. J Lab Clin Med 1955;45:3-17.
2. Weinberger MH. Primary aldosteronism: diagnosis and differentiation of subtypes. Ann Intern Med 1984;100:300-7.
3. Conn JW, Louis LH. Primary aldosteronism: A new clinical entity. Ann Intern Med 1956;44:1-15.
4. Conn JW, Louis LH. Primary aldosteronism: a new clinical entity. Trans Assoc Am Physicians 1955;68:215-31.
5. Viola A, Tizzani D, Monticone S, Crudo V, Galmozzi M, Burrello J, et al. Diagnosis and treatment of unilateral forms of primary aldosteronism. Curr Hypertens Rev 2013;9:156-65.
6. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007;66:607-18.
7. Stewart PM. Mineralocorticoid hypertension. Lancet. 1999;353:1341-7.
8. Ganguly A. Primary aldosteronism. N Engl J Med. 1998;339:1829-34.
9. Amar L, Plouin PF, Steichen O. Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism. Orphanet Journal of Rare Diseases. 2010;5:9.
10. Rossi GP, Bernini G, Caliuni C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006;48:2291-300.
11. Hiramatsu K, Yamada T, Yukiura Y, Komiya I, Ichikawa K, Ishihara M, et al. The screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 1981;141:1589-93.
12. Rossi GP, Seccia TM, Palumbo G, Belfiore A, Bernini G, Caridi G, et al. Within-patient reproducibility of the aldosterone-renin ratio in primary aldosteronism. Hypertension. 2009;55:83-9.
13. Tanabe A, Naruse M, Takagi S, Tsuchiya K, Imaiki T, Takano K. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab. 2003;88:2489-94.
14. Funder JW, Carey RM, Fardella C. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266-81.
15. Hambarian AH, Ioaachimscu AG, Remer EM, Motta-Ramirez G, Bogabathina H, Levin HS, et al. Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab 2005;90:871-7.
16. Stowasser M, Gordon RD. Primary aldosteronism – careful investigation is essential and rewarding. Mol Cell Endocrinol. 2004;217:33-9.
17. Young WF. Minireview: primary aldosteronism – changing concepts in diagnosis and treatment. Endocrinology. 2003;144:2208-1.